TCRX
TScan Therapeutics, Inc.
$1.07
+0.02 (+1.90%)
At close · Jul 7
Market Cap
$70.25M
Shares
65,350,817
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.07
Open$1.07
Day$1.01–1.10
52W$0.83–2.57
Avg vol 30d484K
Short int763K · 1.2% float · 1.9d
Short vol18%
Last earningsMay 6, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+2%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
14%
near low
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−9%
trailing
YTD return
+7%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.17% of float · ▼ -18.4% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+267%
Y/Y
EPS growth
+12%
Y/Y
Free cash flow
$-139.7M
Balance sheet
$119.9M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+2%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.17% of float · ▼ -18.4% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 14%
52-wk high $3
vs 200-day avg -12%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCRX
this stock
TScan Therapeutics, Inc.
|
$70.25M | +7.0% | -86.6% | — | 1.2% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCRX | +8.1% | +9.0% | -8.6% | +9.2% | +7.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +7.2% | +7.6% | -16.1% | +9.1% | -2.7% |